IL285201B2 - EZH2 inhibitors for the treatment of lymphoma - Google Patents

EZH2 inhibitors for the treatment of lymphoma

Info

Publication number
IL285201B2
IL285201B2 IL285201A IL28520121A IL285201B2 IL 285201 B2 IL285201 B2 IL 285201B2 IL 285201 A IL285201 A IL 285201A IL 28520121 A IL28520121 A IL 28520121A IL 285201 B2 IL285201 B2 IL 285201B2
Authority
IL
Israel
Prior art keywords
ezh2
subject
compound
tumor
cancer
Prior art date
Application number
IL285201A
Other languages
English (en)
Hebrew (he)
Other versions
IL285201B1 (en
IL285201A (en
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Publication of IL285201A publication Critical patent/IL285201A/en
Publication of IL285201B1 publication Critical patent/IL285201B1/en
Publication of IL285201B2 publication Critical patent/IL285201B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL285201A 2014-06-17 2015-06-17 EZH2 inhibitors for the treatment of lymphoma IL285201B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013522P 2014-06-17 2014-06-17
US201462036265P 2014-08-12 2014-08-12
PCT/US2015/036310 WO2015195848A1 (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma

Publications (3)

Publication Number Publication Date
IL285201A IL285201A (en) 2021-08-31
IL285201B1 IL285201B1 (en) 2024-01-01
IL285201B2 true IL285201B2 (en) 2024-05-01

Family

ID=54936086

Family Applications (3)

Application Number Title Priority Date Filing Date
IL285201A IL285201B2 (en) 2014-06-17 2015-06-17 EZH2 inhibitors for the treatment of lymphoma
IL309539A IL309539A (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma
IL249438A IL249438A0 (en) 2014-06-17 2016-12-07 ezh2 inhibitors for the treatment of lymphoma

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL309539A IL309539A (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma
IL249438A IL249438A0 (en) 2014-06-17 2016-12-07 ezh2 inhibitors for the treatment of lymphoma

Country Status (21)

Country Link
US (5) US10166238B2 (enExample)
EP (2) EP3157527B1 (enExample)
JP (1) JP6779793B2 (enExample)
KR (2) KR102497728B1 (enExample)
CN (2) CN113289022A (enExample)
AU (3) AU2015277139A1 (enExample)
BR (1) BR112016029492A2 (enExample)
CA (1) CA2952074C (enExample)
DK (1) DK3157527T3 (enExample)
EA (1) EA038337B1 (enExample)
ES (1) ES2948442T3 (enExample)
FI (1) FI3157527T3 (enExample)
HU (1) HUE062158T2 (enExample)
IL (3) IL285201B2 (enExample)
LT (1) LT3157527T (enExample)
MX (2) MX383866B (enExample)
PL (1) PL3157527T3 (enExample)
PT (1) PT3157527T (enExample)
SG (2) SG10201811128RA (enExample)
SI (1) SI3157527T1 (enExample)
WO (1) WO2015195848A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
RU2018145311A (ru) 2012-10-15 2019-02-18 Эпизайм, Инк. Способы лечения рака
AU2014360078A1 (en) 2013-12-06 2016-06-09 Epizyme, Inc. Combination therapy for treating cancer
PT3157527T (pt) 2014-06-17 2023-06-30 Eisai R&D Man Co Ltd Inibidores de ezh2 para tratamento de linfoma
SG10201903356XA (en) * 2014-10-16 2019-05-30 Epizyme Inc Method for treating cancer
SG11201703806XA (en) * 2014-11-17 2017-06-29 Epizyme Inc Method for treating cancer
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
EA201792304A1 (ru) 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
AU2017211331A1 (en) * 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
WO2018136596A1 (en) * 2017-01-20 2018-07-26 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019014191A1 (en) * 2017-07-10 2019-01-17 Constellation Pharmaceuticals, Inc. GENE EXPRESSION INDUCED BY EZH2 INHIBITOR
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
CN114555112A (zh) * 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
JP2023527116A (ja) * 2020-05-28 2023-06-27 エピザイム インコーポレイテッド がんを治療するためのｅｚｈ２阻害剤の使用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JP2014534178A (ja) 2011-09-30 2014-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 癌の処置方法
AU2013232229B2 (en) * 2012-03-12 2017-11-23 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
SG10201608579UA (en) 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
LT2836491T (lt) 2012-04-13 2017-03-27 Epizyme, Inc. Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6461802B2 (ja) 2012-10-15 2019-01-30 エピザイム，インコーポレイティド 置換ベンゼン化合物
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
NZ708563A (en) * 2012-11-01 2019-02-22 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014100080A1 (en) 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
AU2014254392B2 (en) 2013-03-15 2018-05-24 Epizyme, Inc. Substituted benzene compounds
AU2014273946B2 (en) * 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
US10260102B2 (en) 2013-10-09 2019-04-16 Roche Molecular Systems, Inc. Methods and compositions for detecting mutation in the human EZH2 gene
HUE063984T2 (hu) 2013-10-16 2024-02-28 Epizyme Inc Hidroklorid só forma az EZH2 gátlásához
EP3057594A4 (en) 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
AU2014360078A1 (en) 2013-12-06 2016-06-09 Epizyme, Inc. Combination therapy for treating cancer
PT3157527T (pt) 2014-06-17 2023-06-30 Eisai R&D Man Co Ltd Inibidores de ezh2 para tratamento de linfoma
US20190000860A1 (en) 2014-11-06 2019-01-03 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
SG11201703806XA (en) 2014-11-17 2017-06-29 Epizyme Inc Method for treating cancer
JP6544507B2 (ja) 2015-02-09 2019-07-17 日本精機株式会社 ヘッドアップディスプレイ装置
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
KR20170095656A (ko) 2016-02-15 2017-08-23 동부대우전자 주식회사 방열구조를 갖는 세탁기

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. K. KNUTSON ET AL,, SELECTIVE INHIBITION OF EZH2 BY EPZ-6438 LEADS TO POTENT ANTITUMOR ACTIVITY IN EZH2-MUTANT NON-HODGKIN LYMPHOMA, 1 April 2014 (2014-04-01) *

Also Published As

Publication number Publication date
KR102497728B1 (ko) 2023-02-09
PT3157527T (pt) 2023-06-30
EP3157527A1 (en) 2017-04-26
CN106999498A (zh) 2017-08-01
IL285201B1 (en) 2024-01-01
AU2020244382B2 (en) 2022-08-04
EA201692285A8 (ru) 2018-01-31
CA2952074A1 (en) 2015-12-23
WO2015195848A8 (en) 2016-07-07
CN106999498B (zh) 2021-06-08
ES2948442T3 (es) 2023-09-12
KR20170052558A (ko) 2017-05-12
EP3157527B1 (en) 2023-05-24
MX2016016744A (es) 2017-11-30
EP3157527A4 (en) 2018-05-23
HUE062158T2 (hu) 2023-10-28
US20190175604A1 (en) 2019-06-13
AU2015277139A1 (en) 2016-12-22
PL3157527T3 (pl) 2023-08-07
EP4252851A3 (en) 2023-11-22
WO2015195848A1 (en) 2015-12-23
JP2017518334A (ja) 2017-07-06
DK3157527T3 (da) 2023-07-03
SG10201811128RA (en) 2019-01-30
LT3157527T (lt) 2023-07-25
US10166238B2 (en) 2019-01-01
AU2020244382A1 (en) 2020-10-29
EA038337B1 (ru) 2021-08-11
US20240058348A1 (en) 2024-02-22
NZ727108A (en) 2023-09-29
IL309539A (en) 2024-02-01
IL285201A (en) 2021-08-31
MX2021007651A (es) 2021-08-11
AU2022263523A1 (en) 2022-12-08
BR112016029492A2 (pt) 2017-10-17
IL249438A0 (en) 2017-02-28
US20170216300A1 (en) 2017-08-03
US20200022987A1 (en) 2020-01-23
EA201692285A1 (ru) 2017-06-30
CN113289022A (zh) 2021-08-24
US20200323866A1 (en) 2020-10-15
US11642347B2 (en) 2023-05-09
EP4252851A2 (en) 2023-10-04
KR20230031963A (ko) 2023-03-07
JP6779793B2 (ja) 2020-11-04
SI3157527T1 (sl) 2023-09-29
MX383866B (es) 2025-03-14
FI3157527T3 (fi) 2023-07-25
SG11201610273VA (en) 2017-01-27
CA2952074C (en) 2022-08-30

Similar Documents

Publication Publication Date Title
AU2020244382B2 (en) Ezh2 inhibitors for treating lymphoma
US11951109B2 (en) EZH2 inhibitors for treating lymphoma
US20240180919A1 (en) Ezh2 inhibitors for treating cancer
AU2022256115A1 (en) Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
CA2996412A1 (en) Method for treating cancer
HK40097684A (en) Ezh2 inhibitors for treating lymphoma
NZ727108B2 (en) Ezh2 inhibitors for treating lymphoma